Georgia World Congress Center
Room: B308-309
7:00 – 11:00 am

ACTIVITY OVERVIEW
Recent developments in our knowledge of the immune system, the bone marrow micro-environment and the genetic evolution of MDS are optimizing prognostication and management strategies. Intrinsic and extrinsic factors contributing to disease pathogenesis and influencing therapeutic response will be discussed.

TARGET AUDIENCE
This activity is intended for physicians, oncology nurses, nurse practitioners, physician assistants, pharmacists and other health care professionals interested in the treatment and management of patients with Myelodysplastic Syndromes.

LEARNING OBJECTIVES
Upon completion of the educational activity, participants should be able to:

• Describe the various stages of clonal hematopoietic evolution in the elderly
• Identify the complex interplay between the MDS clone and its microenvironment
• Describe molecular background, which plays a role in the dysregulation of the innate and adaptive immune system in MDS
• Discuss both inherited and acquired genetic factors that contribute to MDS pathogenesis and influence prognosis
• Describe the various processes of inflammation and oxidative stress that are associated with the development and (vasculitic) symptoms of MDS
• Utilize objective response predictors and strategies to maximize the successful use of hypomethylating agents
• Apply the objective prognostic factors and measures to identify the patients most suitable for allogeneic stem cell transplant, which may lead to better outcomes

FACULTY

Stephen Nimer, MD – MDSF Chairman

Director, Sylvester Comprehensive Cancer Center
Professor of Medicine, Biochemistry & Molecular Biology
University of Miami Miller School of Medicine
Miami, Florida

Rena Buckstein, MD, FRCPC – Symposium Co-Chair

Director of MDS Research Program and Head of National MDS registry
Head, Hematology Site Group
Odette Cancer Center
Toronto, Canada

Mario Cazzola, MD – Symposium Co-Chair

Professor of Hematology
Department of Molecular Medicine, University of Pavia
Chief, Division of Hematology
Department of Hematology Oncology, Fondazione IRCCS Policlinico S. Matteo
Pavia, Italy

Jude Fitzgibbon, PhD

Professor of Personalised Cancer Medicine
Queen Mary University of London
London, United Kingdom

Rami Komrokji, MD

Leukemia and MDS Section Head
Vice Chair, Malignant Hematology Department
Moffitt Cancer Center
Tampa, Florida

Shahram Kordasti, MD, PhD

King’s College Hospital and King’s College London
Department of Haematological Medicine
London, United Kingdom

John Koreth, MD, PhD

Associate Professor, Harvard Medical School
Senior Physician, Dana-Farber Cancer Institute
Boston, Massachusetts

Luca Malcovati, MD

Associate Professor of Hematology
University of Pavia
Department of Hematology Oncology & Molecular Medicine
Pavia, Italy

AGENDA

CRITERIA FOR SUCCESS

Statements of credit will be awarded based on the participant’s attendance, participation in the pre/post-test and submission of the activity evaluation form. A statement of credit will be available upon completion of an online evaluation/claimed credit form at the conclusion of the live program on this page https://www.mds-foundation.org/learning-center/mds-2017/. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this CME/CE activity, please contact AKH Inc. at tbrignoni@akhcme.com.

ACCREDITATION

CME/CE Credit provided by AKH Inc., Advancing Knowledge in Healthcare

PHYSICIANS

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and the Myelodysplastic Syndromes Foundation, Inc. (MDSF). AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 3.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PHYSICIAN ASSISTANTS

NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

PHARMACY

AKH, Inc., Advancing Knowledge in Healthcare is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
AKH, Inc., Advancing Knowledge in Healthcare approves this knowledge- based activity for 3.5 contact hour(s) (0.35 CEUs). UAN 0077-9999-16-103-L04-P.

NURSING

AKH, Inc., Advancing Knowledge in Healthcare is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
This activity is awarded 3.5 Contact Hours.

Activity is jointly-provided by AKH Inc., Advancing Knowledge in Healthcare and the Myelodysplastic Syndromes Foundation, Inc. (MDSF).

COMMERCIAL SUPPORT

This activity is supported by an educational grant from Celgene Corporation, Onconova Therapeutics, Inc. and Takeda Oncology.

AMERICANS WITH DISABILITIES ACT

AKH Inc, Advancing Knowledge in Healthcare fully intends to comply with the legal requirements of the Americans with Disabilities Act.  If you need assistance, please notify AKH at 904-683-8843 at least two weeks prior to the activity.

*Activity and faculty subject to change